Patent ID: 6451833
Filing Date: 2002-09-17
Classification: C07D

Abstract:
A therapeutic method for treating arteriosclerosis, said method comprising administering to a subject susceptible to or afflicted with such disorder a therapeutically-effective amount of a compound of Formula I: wherein m is one; wherein each of R0 through R1 is independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, n-hexyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl selected from CH3CH2CH&boxH;CH, SC3H7, SC4H9, amino, aminomethyl, aminoethyl, aminopropyl, CH2OH, CH2OCOCH3, CH2Cl, CH2OCH3, CH2OCH(CH3)2, CHO, CH2CO2H, CH(CH3)CO2H, NO2, â€”CONH2, â€”CONHCH3, CON(CH3)2, â€”CH2â€”NHCO2C2H5, â€”CH2NHCO2CH3, â€”CH2NHCO2C3H7, â€”CH2NHCO2CH2(CH3)2, â€”CH2NHCO2C4H9, CH2NHCO2-adamantyl, â€”CH2NHCO2-(1-napthyl), â€”CH2NHCONHCH3, â€”CH2NHCONHC2H5, â€”CH2NHCONHC3H7, â€”CH2NHCONHC4H9, â€”CH2NHCONHCH(CH3)2, â€”CH2NHCONH(1-napthyl), â€”CH2NHCONH(1-adamantyl), â€”CH2CH2CH2CO2H, â€”CH2CH2F, â€”CH2OCONHCH3, â€”CH2OCSNHCH3, â€”CH2NHCSOC3H7, â€”CH2CH2CH2F, â€”CH2ONO2, CF3, CH2OH, Br, Cl, F, I, dimethoxymethyl, 1,1-dimethoxypropyl, 1,1-dimethoxypentyl, hydroxyalkyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, 1,1-difluoro-2-phenylethyl, monofluoromethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, 2-phenylethyl, 1,1-difluoro-3-pheylpropyl, difluoromethyl, CO2H, CO2CH3, CO2CH2CH3, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R3 through R10 is independently selected from hydrido, halo, nitro, trifluoromelhyl, hydroxy, alkoxy, cyano, carboxyl, methoxycarbonyl with the proviso that at least one of R5, R6, R7 and R8 is an acidic group selected from CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl;or a tautomer thereof or a pharmaceutically-acceptable salt thereof.